Diagnostic agent for therapeutic effect on cancer
The present invention provides a diagnostic agent for a therapeutic effect on cancer, containing a compound represented by formula (1-0). (In formula (1-0), R represents —O(CH 2 ) n —, —O(CH 2 ) n OC 2 H 4 —, —CH 2 O(CH 2 ) n —, or —CH 2 O(CH 2 ) n OC 2 H 4 —, n represents an integer of 1 to 5, and Q 1 represents F or —OCH 3 .)
1. A method for diagnosing a therapeutic effect on cancer, comprising:
a step of performing a cancer therapy to a subject contracting cancer,
a step of administering a compound represented by formula (1-0) to the subject;
in formula (1-0), R represents —O(CH 2 ) n —, —O(CH 2 ) n OC 2 H 4 —, —CH 2 O(CH 2 ) n —, or —CH 2 O(CH 2 ) n OC 2 H 4 —, n represents an integer of 1 to 5, and Q 1 represents F or —OCH 3 ,
a step of detecting the compound in the cancer, and
a step of analyzing an accumulation amount of the compound in the cancer quantitatively.
2. The method according to claim 1 , wherein the compound is represented by formula (1-0′);
3. A method for diagnosing a therapeutic effect on cancer, comprising:
a step of performing a cancer therapy to a subject contracting cancer,
a step of administering a compound represented by formula (1-0) to the subject;
in formula (1-0) , R represents —O(CH 2 ) n —, —O(CH 2 ) n OC 2 H 4 —, —CH 2 O(CH 2 ) n —, or —CH 2 O(CH 2 ) n OC 2 H 4 —, n represents an integer of 1 to 5, and Q 1 represents 18 F or —O 11 CH 3 ,
a step of detecting the compound in the cancer, and
a step of analyzing an accumulation amount of the compound in the cancer quantitatively.
4. The method according to claim 3 , wherein the compound is represented by formula (1-0′);
5. The method according to claim 3 , wherein the compound is detected by positron emission tomography (PET).
6. The method according to claim 4 , wherein the compound is detected by positron emission tomography (PET).
7. The method according to claim 1 , wherein the subject is a human.
8. The method according to claim 3 , wherein the subject is a human.
9. The method according to claim 1 , wherein the cancer therapy is selected from radiation therapy and chemotherapy.
10. The method according to claim 3 , wherein the cancer therapy is selected from radiation therapy and chemotherapy.
11. The method according to claim 1 , wherein the compound is administered to the subject at two to ten days after the cancer therapy is started.
12. The method according to claim 3 , wherein the compound is administered to the subject at two to ten days after the cancer therapy is started.